PMID- 12959635
OWN - NLM
STAT- MEDLINE
DCOM- 20040414
LR  - 20181113
IS  - 0312-5963 (Print)
IS  - 0312-5963 (Linking)
VI  - 42
IP  - 12
DP  - 2003
TI  - Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for 
      clinical practice.
PG  - 1043-57
AB  - Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially 
      from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic 
      properties. Some of the pharmacodynamic features of enoxaparin that distinguish 
      it from UFH are a higher ratio of anti-Xa to anti-IIa activity, more consistent 
      release of tissue factor pathway inhibitor, weaker interactions with platelets 
      and less inhibition of bone formation. Enoxaparin has a higher and more 
      consistent bioavailability after subcutaneous administration than UFH, a longer 
      plasma half-life and is less strongly bound to plasma proteins. These properties 
      mean that enoxaparin provides a more reliable anticoagulant effect without the 
      need for laboratory monitoring, and also offers the convenience of once-daily 
      administration. Clinical studies have confirmed that these pharmacological 
      advantages translate into improved outcomes. There are important pharmacokinetic 
      and pharmacodynamic differences between enoxaparin, other LMWHs and UFH, and 
      therefore these molecules cannot be regarded as interchangeable.
FAU - Fareed, Jawed
AU  - Fareed J
AD  - Department of Pathology, Loyola University Medical Center, Maywood, Illinois, 
      USA. jfareed@lumc.edu
FAU - Hoppensteadt, Debra
AU  - Hoppensteadt D
FAU - Walenga, Jeanine
AU  - Walenga J
FAU - Iqbal, Omer
AU  - Iqbal O
FAU - Ma, Qing
AU  - Ma Q
FAU - Jeske, Walter
AU  - Jeske W
FAU - Sheikh, Taqdees
AU  - Sheikh T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Age Factors
MH  - Anticoagulants/*pharmacokinetics/pharmacology/therapeutic use
MH  - Biological Availability
MH  - Clinical Trials as Topic
MH  - Enoxaparin/*pharmacokinetics/pharmacology/therapeutic use
MH  - Female
MH  - Half-Life
MH  - Humans
MH  - Obesity/metabolism
MH  - Pregnancy
MH  - Renal Insufficiency/metabolism
RF  - 81
EDAT- 2003/09/10 05:00
MHDA- 2004/04/15 05:00
CRDT- 2003/09/10 05:00
PHST- 2003/09/10 05:00 [pubmed]
PHST- 2004/04/15 05:00 [medline]
PHST- 2003/09/10 05:00 [entrez]
AID - 42123 [pii]
AID - 10.2165/00003088-200342120-00003 [doi]
PST - ppublish
SO  - Clin Pharmacokinet. 2003;42(12):1043-57. doi: 10.2165/00003088-200342120-00003.